Linvoseltamab De-Escalation

Pharmacodynamically Monitored Linvoseltamab Dosing De-Escalation in Relapsed Multiple Myeloma

More Information

Trial Status
Accepting patients
Trial Phase
Phase 1/2
Enrollment
30 patients (estimated)
Tags
Bispecific Antibody, B-Cell Maturation Antigen (BCMA)
Trial Type
Treatment
Last Update
SparkCures ID
2202
NCT Identifier
NCT07181941

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 850-0650

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.